We first compared the efficacy of three MEK inhibitors (trametinib, cobimetinib, and binimetinib) combined with anti‐EGFR antibodies in two randomly chosen KRAS mutated CRC PDX models in vivo, which have previously shown effective in vitro. Here, KRAS is linked to colorectal carcinoma.